Review Article

Peroxisome Proliferator-Activated Receptors: “Key” Regulators of Neuroinflammation after Traumatic Brain Injury

Philip F. Stahel,1 Wade R. Smith,1 Jay Bruchis,1 and Craig H. Rabb2

1 Department of Orthopedic Surgery, Denver Health Medical Center, School of Medicine, University of Colorado, 777 Bannock Street, Denver, CO 80204, USA
2 Division of Neurosurgery, Department of Surgery, Denver Health Medical Center, School of Medicine, University of Colorado, 777 Bannock Street, Denver, CO 80204, USA

Correspondence should be addressed to Philip F. Stahel, philip.stahel@dhha.org

Received 24 December 2007; Accepted 29 January 2008

Recommended by Paul Drew

Traumatic brain injury is characterized by neuroinflammatory pathological sequelae which contribute to brain edema and delayed neuronal cell death. Until present, no specific pharmacological compound has been found, which attenuates these pathophysiological events and improves the outcome after head injury. Recent experimental studies suggest that targeting peroxisome proliferator-activated receptors (PPARs) may represent a new anti-inflammatory therapeutic concept for traumatic brain injury. PPARs are “key” transcription factors which inhibit NFκB activity and downstream transcription products, such as proinflammatory and proapoptotic cytokines. The present review outlines our current understanding of PPAR-mediated neuroprotective mechanisms in the injured brain and discusses potential future anti-inflammatory strategies for head-injured patients, with an emphasis on the putative beneficial combination therapy of synthetic cannabinoids (e.g., dexanabinol) with PPARα agonists (e.g., fenofibrate).

Copyright © 2008 Philip F. Stahel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Research efforts in recent years have provided increasing evidence that the intracerebral inflammatory response is in large part responsible for the devastating neuropathological sequelae and poor outcome of traumatic brain injury [1–3]. The extent of brain damage is determined by primary and secondary injury patterns. While the primary injury results from mechanical forces applied to the skull and brain at the time of impact, secondary brain injury occurs as a delayed consequence of trauma [4–7]. Secondary brain injuries are mediated by endogenous pathophysiological processes which lead to an overwhelming neuroinflammation in the injured brain [6, 8–10]. The main risk factors for developing secondary brain injuries are hypoxemia and systemic hypotension which occur frequently in the trauma patient [11, 12]. These conditions contribute to the ischemic brain damage and perpetuate the intracerebral inflammatory reaction through ischemia/reperfusion-mediated mechanisms [13]. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors of the nuclear receptor superfamily which have recently been shown to exert anti-inflammatory properties in acute neurological disorders. These include cerebrovascular stroke, intracerebral hemorrhage, spinal cord injury, and traumatic brain injury [14–21]. The present paper provides an overview on the so far known anti-inflammatory properties of PPARs in brain injury and discusses potential pharmacological properties of PPAR agonists as future neuroprotective agents.

2. BIOLOGICAL FUNCTIONS OF PPARs

PPARs are nuclear membrane-associated transcription factors belonging to the nuclear receptor family [22]. Three isoforms with a differential tissue distribution have been described: PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3) [23, 24]. While PPARβ/δ has an ubiquitous expression, PPARα and PPARγ are mainly expressed in tissues...
with high fatty acid catabolism, such as adipose tissue, liver, kidney, and skeletal muscle [25]. Mechanistically, PPARs are activated by heterodimerization with the retinoid-X receptor (RXR) into biologically active transcription factors. PPAR-RXR heterodimers induce the transcription of candidate genes by binding to so-called peroxisome proliferator-response elements (PPRE’s) consisting of DNA-specific sequences (see Figure 1).

PPARs exert a wide variety of physiological functions [24, 26]. They play a central role in the regulation of lipid and lipoprotein metabolism and glucose homeostasis, and have been shown to mediate cellular proliferation and programmed cell death (apoptosis) [27–31]. PPARs have furthermore been involved in bone metabolism and in pathologies of the cardiovascular system and the lung [32–35]. PPARα has been attributed important immunological functions due to its expression on monocytes/macrophages, T cells, and vascular endothelial cells. PPARγ appears to play a crucial role in the regulation of proliferation and differentiation of various cell types. While the biological role of PPARβ/δ has not been defined in detail, recent data imply an antiapoptotic and anti-inflammatory effect after tissue injury, both in vitro and in vivo [29].

From an immunological viewpoint, PPARs have been identified as important regulators of inflammatory gene expression [36–40]. PPARs have also been shown to attenuate adaptive immune responses by inhibiting helper T cell functions and by mediating apoptosis of B cells [41, 42]. PPARs are activated by naturally occurring fatty acid derivatives, eicosanoides, and by synthetic pharmacological agents, such as fibrates (PPARα) and glitazones (PPARγ) [18, 22, 43]. PPAR ligands have been shown to exert anti-inflammatory activities in various cell types by inhibiting the gene expression for proinflammatory cytokines, metalloproteinases, and hepatic acute-phase proteins.

### 3. PPARs: “KEY” REGULATORS OF NEUROINFLAMMATION

Mechanistically, the activation of PPARα has been shown to inhibit proinflammatory gene transcription by repressing the central inflammatory transcription factor, nuclear factor-κB (NF-κB) [43–45]. Along with suppression of NF-κB, PPARα acts by inhibition of signal transduction through activator protein-1 (AP-1) signaling [43]. It appears that the inhibitory effect of PPARα on these crucial inflammatory transcription factors creates a negative feedback loop for controlling acute posttraumatic inflammation [44–46]. First in vivo data on the involvement of PPARs in the regulation of inflammation were reported from studies in PPARα knockout mice [47]. Cuzzocrea et al. showed that the targeted deletion of the PPARα gene leads to a significantly increased inflammatory response in different experimental models of acute inflammation outside the central nervous system (CNS) [47]. Within the CNS, the constitutive expression of PPARs has been described for some time [48, 49]. Interestingly, PPAR gene expression was detected not only on vascular endothelial cells in the brain and spinal cord, but also on resident cells in the CNS, such as neurons and glial cells [49].

### 4. ROLE OF PPARs IN CNS INJURY

In recent years, experimental studies in models of cerebral ischemia/reperfusion injury, ischemic stroke, intracerebral hemorrhage, and spinal cord injury have revealed a crucial role of PPARs in attenuating neuroinflammation and neuronal cell death in the injured CNS (see Table 1) [14–16, 19, 20, 50–52]. PPARα gene-deficient mice (PPARα−/−) were shown to have a significantly worsened neurological outcome, associated with an increased neuroinflammatory response to experimental spinal cord injury, as compared to wild-type littermates [16]. The postulated neuroprotective effects of natural PPARα ligands include the attenuation of polymorphonuclear leukocyte (PMNL) recruitment and associated neurotoxicity, as determined by a significantly reduced expression of myeloperoxidase in the injured spinal cord of PPARα−/− mice [16]. In addition, tumor necrosis factor (TNF), a “key” mediator of neuroinflammation and neurotoxicity, was shown to be upregulated and associated with neuronal apoptosis in the injured spinal cord of PPARα−/− mice [16]. In traumatic brain injury, experimental studies in the past decade have shown that TNF is upregulated in the intracranial compartment within a few hours after trauma, and contributes to secondary neuronal injury [53–55]. The deleterious neurotoxic effects were shown to be abrogated by pharmacological inhibition of TNF [56]. Since PPARs inhibit proinflammatory gene transcription by attenuating NF-κB signaling [43–45], the potent PPAR-mediated neuroprotective effects may be dependent on inhibition of NF-κB-dependent proinflammatory cytokines released in the injured brain, such as TNF, interleukin (IL)-1α, IL-8, IL-12, and IL-18 [57–61]. The central role of NF-κB signaling in inflammation and oxidative stress explains why PPARs have been considered possible targets for neuroprotection in in-
Table 1: Selected publications on the role of PPARs in CNS injury and inflammation.

<table>
<thead>
<tr>
<th>Models of CNS injury and neuroinflammation</th>
<th>PPAR isotype</th>
<th>Main findings</th>
<th>Reference no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Different models of CNS injury</td>
<td>PPARγ</td>
<td>Review on the mechanisms of neuroprotection by PPARγ agonists</td>
<td>Kapadia et al. [20]</td>
</tr>
<tr>
<td>Different models of CNS injury PPARα, PPARγ</td>
<td></td>
<td>Review on pharmacological neuroprotection by PPARs</td>
<td>Bordet et al. [14]</td>
</tr>
<tr>
<td>Brain inflammation</td>
<td>PPARγ</td>
<td>Review on regulation of microglial activation by PPARγ agonists</td>
<td>Bernardo and Minghetti [63]</td>
</tr>
<tr>
<td>Spinal cord injury</td>
<td>All isotypes</td>
<td>Review on the role of PPAR signal transduction in spinal cord injury</td>
<td>Van Neerven and Mey [15]</td>
</tr>
<tr>
<td>Spinal cord injury</td>
<td>PPARα</td>
<td>Experimental model of spinal cord injury in PPARα gene knockout mice. Lack of PPARα leads to worse outcome and increased neuroinflammation.</td>
<td>Genovese et al. [16]</td>
</tr>
<tr>
<td>Cerebral ischemia/reperfusion injury</td>
<td>PPARγ</td>
<td>The PPARγ agonists rosiglitazone and pioglitazone exert neuroprotective effects in a rat model of cerebral ischemia/reperfusion injury by reducing neuroinflammation and oxidative stress.</td>
<td>Collino et al. [50]</td>
</tr>
<tr>
<td>Intracerebral hemorrhage</td>
<td>PPARγ</td>
<td>PPARγ expressed by microglia and macrophages promotes the resolution of intracerebral hemorrhage and attenuates the neuroinflammatory response.</td>
<td>Zhao et al. [19]</td>
</tr>
<tr>
<td>Traumatic brain injury</td>
<td>PPARα</td>
<td>The PPARα agonist fenofibrate reduces brain edema and improves the neurological outcome after experimental fluid percussion brain injury in male Sprague-Dawley rats.</td>
<td>Besson et al. [21]</td>
</tr>
<tr>
<td>Traumatic brain injury</td>
<td>PPARα</td>
<td>The PPARα agonist fenofibrate promotes neurological recovery by reducing inflammation and oxidative stress in rat brains after experimental fluid percussion brain injury.</td>
<td>Chen et al. [17]</td>
</tr>
<tr>
<td>Neuroinflammation</td>
<td>All isotypes</td>
<td>Review on the interaction between cannabinoids and PPARs as inhibitors of neuroinflammation</td>
<td>Sun and Bennett [83]</td>
</tr>
</tbody>
</table>

Inflammatory CNS diseases, including traumatic brain injury [14, 20, 62, 63].

5. PHARMACOLOGY OF HEAD INJURY: ARE PPAR-AgonISTS AND CANNABINOIDs THE LONG SOUGHT “GOLDEN BULLET”?

A wide variety of natural and synthetic PPARγ agonists have been described in recent years as regulators of microglial activation and cerebral inflammation [63]. For example, the thiazolidinedione pioglitazone has been shown to reduce the extent of neuroinflammation and the severity of disease in experimental autoimmune encephalomyelitis (EAE), the animal model for multiple sclerosis (MS) [64, 65]. A recent case report described the impressive clinical improvement of a patient with chronic progressive MS, after a 3-year period of treatment with pioglitazone [66]. This unexpected clinical recovery implies that PPARγ agonists may represent a promising new strategy for attenuating neuroinflammation in patients with CNS autoimmune diseases [62, 63, 67].

In cerebrovascular stroke, the combination therapy of a PPARγ agonist (rosiglitazone) with an antiexcitotoxic glutamate receptor antagonist (MK-801) led to an improved neurological recovery in rats undergoing middle cerebral artery occlusion [18]. A study by another group assessed the therapeutic efficacy of two different PPARγ agonists, rosiglitazone and pioglitazone, in a rat model of cerebral ischemia/reperfusion injury [50]. The authors showed that the pretreatment with either compound led to a significant attenuation of inflammation and oxidative stress in injured rat brains [50].

Pharmacological ligands to PPARα, such as fenofibrate, have also been shown to exert neuroprotective effects in inflammatory CNS conditions. Deplanque et al. demonstrated a significant neuroprotective effect of fenofibrate administration in C57BL/6 mice with cerebrovascular stroke [68]. The authors suggested that PPARα may represent a new pharmacological target to reduce the neuroinflammatory and neuropathological sequelae of cerebrovascular stroke [68].

In traumatic brain injury, the PPARα agonist fenofibrate appears to represent a highly promising new anti-inflammatory compound. Besson et al. assessed the pharmacological role of fenofibrate in a model of experimental fluid-percussion injury in adult male Sprague-Dawley rats [21]. The authors revealed that the administration of fenofibrate during a clinically relevant therapeutic “time window of opportunity” at 1 hour after trauma mediated a significant posttraumatic neuroprotection. This was demonstrated by improved neurological scores in the fenofibrate group at 24 hours and 7 days after trauma, compared to vehicle-treated animals [21]. Morphologically, fenofibrate treatment resulted in significantly decreased extent of brain edema at 24 hours after head injury, compared to the placebo group. The authors furthermore described a marked reduction in intercellular adhesion molecule (ICAM)-1 expression at the protein level by immunohistochemistry in injured rat brain...
sections after fenofibrate administration [21]. This finding implies a reduced extent of intracerebral immunoactivation and neuroinflammation in rats treated by the PPARα agonist, compared to vehicle controls.

A more recent follow-up study by the same research group assessed the role of PPARα in modulating the oxidative stress in the injured rat brain [17]. Oxidative stress and ischemia/reperfusion-mediated injuries contribute significantly to the extent of posttraumatic intracerebral inflammation and delayed secondary brain damage after head injury [13, 69, 70]. Pathophysiologically, confused brain areas are surrounded by a penumbra zone which is hypoperfused due to traumatic vascular damage, loss of cerebrovascular autoregulation, and systemic hypotension. After resuscitation, the hypoperfused, ischemic brain areas in the penumbra zone are reperfusion, which leads to activation of the complement cascade and of reactive oxygen intermediates by activation of the xanthine oxidase [71, 72]. Oxygen-derived free radicals such as hydroxyl ions, hydrogen peroxide, and superoxide anion induce lipid peroxidation, cell membrane disintegration, and delayed neuronal cell death (see Figure 2). Lipid peroxidation is facilitated in the brain due to its genuine vulnerability to oxidative stress based on specific morphological characteristics, such as a high ratio of “membrane to cytoplasm” and high levels of polyunsaturated fatty acids in the CNS [70]. In addition to reactive oxygen intermediates, the generation of nitric oxide (NO) by inducible NO synthase (iNOS) up-regulation also occurs after head injury and adds to the extent of secondary brain damage [73]. Metabolites emerging from the interaction between superoxide anion and NO, such as the highly reactive oxidant peroxynitrite, have been shown to mediate neurotoxicity and delayed neuronal cell death after traumatic brain injury [74].

The pharmacological administration of the PPARα agonist fenofibrate after experimental fluid-percussion injury resulted in a significant decrease of intracerebral iNOS expression [17]. This was associated with a decreased neuroinflammation in the injured brain and an improved neurological recovery after trauma [17]. These important findings imply that the attenuation of oxidative stress may represent a “key” mechanistic aspect of PPAR-mediated neuroprotection after head injury. The pleiotropic beneficial effects of PPARs in the injured brain, however, are far from being elucidated in detail until present. For example, in contrast to PPARα, no studies have yet been performed to analyze the effect of PPARγ in experimental models of traumatic brain injury (see Table 1).

Despite increasing insights into the pathophysiological mechanisms of posttraumatic neuroinflammation and neurodegeneration, clinical neuroprotection trials have failed to provide a benefit of anti-inflammatory pharmacological strategies with regard to the outcome after head injury [75, 76]. Cannabinoids have recently evolved as a promising new therapeutic avenue for neuroprotection after head injury [77–79]. This group of compounds consists of natural (endocannabinoids) and synthetic ligands, such as dexanabinol (HU-211). The endocannabinoid 2-arachidonoyl glycerol (2-AG) has received increased attention in recent years due to its strong neuroprotective effect after head injury, by inhibition of proinflammatory cytokines, reactive oxygen intermediates, and excitotoxic aminoacids, such as glutamate [80, 81]. The pharmacological agent dexanabinol was shown to mediate neuroprotection by inhibition of TNF production in injured rodent brains [77, 82] and was recently proposed as an effective neuroprotective strategy to reduce the extent of secondary brain injury in humans (see Figure 2) [78, 79]. Dexanabinol (HU-211) is a nonpsychotropic, synthetic cannabinoid which exerts beneficial effects by cytokine inhibition and radical scavenging associated with reduction of brain edema [77–79, 82]. Cannabinoids were attributed a new role as neuroprotective agents by agonistic action to PPARs [83]. The functional interaction between cannabinoids and PPARs was first described based on the finding of oleylthanolamide (OEA), a lipid derive structurally related to anandamide, as a regulator of feeding behavior in rats through activation of PPARα [68, 84]. Aside from OEA, which is a low-affinity agonist to cannabinoid receptors, other cannabinoids were recently described as PPAR ligands [83]. As such, Δ2-tetrahydrocannabinol (THC) was found to activate PPARγ in human cell lines [85]. Of particular interest for neuroprotection in traumatic brain injury is the finding that the potent endocannabinoid 2-AG [80, 81] has been found to suppress the proinflammatory cytokine IL-2 through PPARγ signaling, independent of 2-AG binding to cannabinoid re-

![Figure 2: Working hypothesis of PPAR-mediated mechanisms of neuroprotection after traumatic brain injury.](image-url)
ceptors [86]. Future studies will have to determine whether cannabinoids represent the long sought “golden bullet” for reduction of secondary brain damage after head injury. It seems reasonable to suggest that a combination of neuroprotective cannabinoids, such as dexamabnol, with other potent anti-inflammatory therapeutic agents, such as synthetic PPAR ligands, may represent a promising new therapeutic avenue for improving the outcome of traumatic brain injury.

REFERENCES


[30] S. Kersten, “Peroxisome proliferator activated receptors and...


